Develops an oral antibiotic for adults with complicated urinary tract infections and pursues treatments for rare diseases and diseases with high unmet need.
10-K for FY2025, filed Mar 26, 2026
Drug partners pay upfront and when development or sales milestones are reached for licensed drug rights; Spero may also receive royalties tied to licensed-product sales.
10-K for FY2025, filed Mar 26, 2026
10-K for FY2025, filed Mar 26, 2026
FY2025 revenue by product or service ↗$66.8M
10-K for FY2025, filed Mar 26, 2026
$66.8M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Grant Revenue
|
11% |
Grant Revenue, FY2025
$7.2M Sources
|
|
|
Collaboration revenue - related party
Licensed
10-K for FY2025, filed Mar 26, 2026 |
70% |
Collaboration revenue - related party, FY2025
$47M Sources
|
Licensed |
|
Collaboration revenue
|
19% |
Collaboration revenue, FY2025
$12.6M Sources
|
Drug companies license rights to develop and commercialize Spero’s drug candidates; GSK holds rights for tebipenem in most territories, while Meiji retains rights in certain Asian territories.
10-K for FY2025, filed Mar 26, 2026In September 2022, we entered into the GSK License Agreement, for the development, manufacturing and commercialization of tebipenem HBr.…View ↗
Yes. It kept 13 cents of every revenue dollar as net income in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$44.3MView ↗
8-K, filed Jul 14, 2026
On July 8, 2026, Spero Therapeutics, Inc. (the “Company”) entered into a license agreement (the “Innovent Agreement”) with Innovent…View ↗
8-K, filed Jun 22, 2026
On June 17, 2026, Spero Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration…View ↗
Growing. Revenue grew 3.7x in 4 years, from $18.3M in FY2021 to $66.8M in FY2025, about 38% a year.
Portfolio focus
The older report presents an oral treatment for NTM lung disease as the lead program and describes other infection candidates. The latest report says earlier-stage programs have ended and focuses on supporting GSK’s FDA process for tebipenem while exploring other clinical-stage candidates.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 26, 2026We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for…View ↗
In March 2025, following a reprioritization of our programs, we announced that we were no longer pursuing a Phase 2 clinical trial for…View ↗
Loading...